Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 7:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 132 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: physician's standard of care Clear all
Not listed Phase 2 Interventional

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

NCT04197687
View directory record Official record
Conditions
Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Multi-epitope HER2 Peptide Vaccine TPIV100, Pertuzumab, Placebo Administration, Sargramostim, Trastuzumab, Trastuzumab Emtansine
Biological · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older · Female only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
30
States / cities
Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced Sep 28, 2026, 7:31 PM EDT
Recruiting Phase 4 Interventional

Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study

NCT04191681
View directory record Official record
Conditions
Stage D Heart Failure
Interventions
Sacubitril-Valsartan, Usual care (standard-of-care) arm
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Sep 28, 2026, 7:31 PM EDT
Completed Phase 2 Interventional Results available

Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer

NCT01725165
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
Clinical Observation, External Beam Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Standard Follow-Up Care, Therapeutic Conventional Surgery
Other · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
2
States / cities
Denver, Colorado • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Sep 28, 2026, 7:31 PM EDT
Recruiting Phase 2 Interventional

Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

NCT07148947
View directory record Official record
Conditions
Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm
Interventions
Pacritinib, Decitabine, Decitabine and Cedazuridine, Azacitidine, Survey Administration, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
Drug · Other · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 28, 2026, 7:31 PM EDT
Completed No phase listed Observational

Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy

NCT04014764
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Lymphoma, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Myeloproliferative Neoplasm
Interventions
This is a non-interventional study
Other
Lead sponsor
Notable Labs
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
Bakersfield, California • San Luis Obispo, California • Grand Junction, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Sep 28, 2026, 7:31 PM EDT
Withdrawn Not applicable Interventional

Influence of Pharmacist and Student Pharmacists on Medication Adherence in Community Pharmacy Setting in Underserved Population

NCT04376112
View directory record Official record
Conditions
Diabetes, Medication Non Adherence, Blood Pressure, Pharmacist-Patient Relations
Interventions
Pharmacist and pillpack intervention, Standard of care
Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Bernardino, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Sep 28, 2026, 7:31 PM EDT
Active, not recruiting Not applicable Interventional

A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

NCT03127631
View directory record Official record
Conditions
Prostate Cancer, Cardiovascular Disease
Interventions
Nutrition, Exercise, Smoking cessation, Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin), ACE inhibitor
Behavioral · Drug
Lead sponsor
McMaster University
Other
Eligibility
45 Years and older · Male only
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
4
States / cities
Augusta, Georgia • Kansas City, Kansas • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 28, 2026, 7:31 PM EDT
Not listed Not applicable Interventional

Impact of Integrated Care Pathways for Prevention of Post-operative Urinary Retention (POUR)

NCT03863743
View directory record Official record
Conditions
Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee, Urinary Retention
Interventions
integrated care pathway, physician's standard of care
Other
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 28, 2021 · Synced Sep 28, 2026, 7:31 PM EDT
Completed No phase listed Observational Results available

Evaluating Cancer Survivorship Care Models

NCT02362750
View directory record Official record
Conditions
Quality of Life, Cancer
Interventions
Consultative Specialized Survivorship Clinic (CSSC), Longitudinal Specialized Survivorship Clinic (LSSC), Oncology Embedded Survivorship Clinic (OESC)
Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
991 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 28, 2026, 7:31 PM EDT
Recruiting Phase 2 Interventional

Embryonal Tumor With Multilayered Rosettes

NCT06861244
View directory record Official record
Conditions
Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos
Interventions
Radiotherapy (RT), Chemotherapy Drug, Cancer - Physician's Choice, Non-Investigational Surgical Resection, Temozolomide, Tumor Tissue Sample, Blood Sample, Cerebrospinal Fluid (CSF) Sample
Radiation · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
8
States / cities
Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 28, 2026, 7:31 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery

NCT01561391
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
activated recombinant human factor VII, factor IX, factor VIII
Drug · Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
5 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
14
States / cities
Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Sep 28, 2026, 7:31 PM EDT
Completed No phase listed Observational

Radiolabeled Glass Beads in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery

NCT00532740
View directory record Official record
Conditions
Liver Cancer, Metastatic Cancer
Interventions
Yttrium Y 90 glass microspheres
Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Sep 28, 2026, 7:31 PM EDT
Completed Phase 3 Interventional Results available

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy

NCT01419197
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab emtansine, Treatment of physician's choice
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
59
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Hayward, California + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced Sep 28, 2026, 7:31 PM EDT
Not listed Phase 4 Interventional

IO vs IV Vancomycin in Tourniquetless TKA

NCT05705843
View directory record Official record
Conditions
Infection, Surgical Site
Interventions
Intraosseous Vancomycin Injection, Intravenous Vancomycin
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
19 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Sep 28, 2026, 7:31 PM EDT
Recruiting Phase 3 Interventional

Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.

NCT07465718
View directory record Official record
Conditions
Wilson's Disease
Interventions
TETA 4HCl formulation, D-Penicillamine
Drug
Lead sponsor
Orphalan
Industry
Eligibility
8 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Denver, Colorado • New Haven, Connecticut • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 28, 2026, 7:31 PM EDT
Completed Not applicable Interventional

PACE-PC: Primary Care Management of Adolescent Obesity

NCT00415974
View directory record Official record
Conditions
Obesity, Overweight, Weight Loss
Interventions
Physician Counseling, Health Educator, Phone Counseling, Health promotion materials on physical activity and nutrition
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
11 Years to 13 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2012 · Synced Sep 28, 2026, 7:31 PM EDT
Recruiting Phase 2 Interventional

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

NCT06831136
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Neoadjuvant Chemotherapy (NAC), Immunotherapy (pembrolizumab), Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA)
Drug · Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 28, 2026, 7:31 PM EDT
Completed Phase 2 Interventional Results available

Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

NCT02282345
View directory record Official record
Conditions
Breast Adenocarcinoma, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, HER2/Neu Negative, Invasive Breast Carcinoma
Interventions
Laboratory Biomarker Analysis, Talazoparib
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Sep 28, 2026, 7:31 PM EDT
Recruiting Phase 2 Interventional

Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

NCT06905509
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Nodal Marginal Zone Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cytarabine, Dexamethasone, Epcoritamab, Etoposide Phosphate, Gemcitabine, Ifosfamide, Multigated Acquisition Scan, Oxaliplatin, Rituximab
Procedure · Drug · Biological
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 28, 2026, 7:31 PM EDT
Recruiting Phase 3 Interventional

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803
View directory record Official record
Conditions
Prostate Cancer
Interventions
Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
45
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 28, 2026, 7:31 PM EDT
Completed Phase 3 Interventional Results available

The BEACON Study (Breast Cancer Outcomes With NKTR-102)

NCT01492101
View directory record Official record
Conditions
Locally Recurrent Breast Cancer, Metastatic Breast Cancer
Interventions
NKTR-102, Treatment of Physician's Choice (TPC)
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
88
States / cities
Flagstaff, Arizona • Burbank, California • Los Angeles, California + 74 more
Source: ClinicalTrials.gov public record
Updated May 31, 2021 · Synced Sep 28, 2026, 7:31 PM EDT
Active, not recruiting Not applicable Interventional

Time-Restricted Eating for Type II Diabetes: TRE-T2D

NCT05365529
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Time Restricted Feeding, Diabetes type2
Interventions
Time-Restricted Eating, Standard of Care
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 28, 2026, 7:31 PM EDT
Recruiting Phase 3 Interventional

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

NCT06513962
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Best Practice, Biospecimen Collection, Electronic Health Record Review, Survey Administration, Triptorelin Pamoate
Other · Procedure · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 39 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
201
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 28, 2026, 7:31 PM EDT
Withdrawn Not applicable Interventional

iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes

NCT03446638
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
FDA-approved drug or combination of drugs, FLAG induction, 7 + 3 induction, Low-dose cytarabine, Supportive care alone, Computational biology simulations software
Drug · Other · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Sep 28, 2026, 7:31 PM EDT